All articles by Vishnu Priyan

Vishnu Priyan

Xenon Pharmaceuticals reports data from trial of MDD therapy

XEN1101 was found to be well-tolerated, with comparable adverse event rates across all treatment groups.

Acadia Pharmaceuticals begins trial of Alzheimer’s psychosis drug

The trial is designed to analyse the safety and efficacy of 30mg and 60mg doses of ACP-204 versus those of placebo.

TC BioPharm receives FDA approval for AML cell therapy trial

OmnImmune is an allogeneic unmodified cell therapy that consists of activated and expanded gamma delta T-cells.

Roivant and Priovant’s lupus drug fails to meet trial endpoint

Based on brepocitinib’s favourable safety and tolerability profile in the trial, Priovant will advance it for other indications.

GSK reports positive data from Phase III multiple myeloma trial

Interim efficacy assessment data showed that the trial met the primary endpoint of progression-free survival.

Royal Free London and UCL recruit patients for liver disease app trial

The trial is supported by a £2m grant from the UK National Institute for Health and Care Research.

University of Queensland’s vaccine shows virus-neutralising effect in trial

The Queensland and Australian governments, as well as various partners, supported the trial of the re-engineered molecular clamp.

AIM ImmunoTech concludes dosing in Phase II post-Covid drug trial

The company anticipates reporting topline findings from the trial in the first quarter of next year.

FDA grants IND approval for Senhwa’s trial of Silmitasertib 

The trial will analyse whether early treatment with Silmitasertib hinders CAP progression.

Immix to assess cell therapy in Phase Ib/IIa AL amyloidosis trial

The open-label trial is designed to assess the efficacy and safety of NXC-201.